The burgeoning landscape of therapy for weight management and type 2 glucose intolerance is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant distinctions in their pharmacological profiles and clinical investigation results are

Arriving in the landscape of obesity management, retatrutide represents a different approach. Different from many available medications, retatrutide works as a dual agonist, at once engaging both GLP-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) receptors. This concurrent engagement fosters several helpful effects, such